Table 1.
Demographics, comorbidities, and GD treatment of the full study cohort (n = 181).
| All patients (N = 181) |
Pediatric (n = 31) |
Adult (n = 150) |
|
|---|---|---|---|
| Demographics | |||
| Age, mean (sd), y | 43 (21.7) | 8.5 (4.5) | 50.1 (16.2) |
| Sex, Females, no. (%) | 83 (46) | 15 (48) | 68 (45) |
| AJ Ancestry, no. (%) | 154 (85) | 25 (81) | 129 (86) |
| GBA N370S/N370S, no. (%) | 110 (61) | 16 (52) | 94 (63) |
| BMI, mean (sd) | N/A | N/A | 26.5 (4.6) |
| No. of COVID-19 Symptoms, mean (sd) | 0.7 (1.7) | 0.4 (0.6) | 0.8 (1.8) |
| No. of Comorbidities, mean (sd) | 0.7 (1.0) | 0.2 (0.6) | 0.8 (1.0) |
| Comorbidities, no. (%) | |||
| High blood pressure | 24 (13) | – | 24 (16) |
| Diabetes | 4 (2) | – | 4 (3) |
| Overweight | 9 (5) | – | 9 (6) |
| Lung disease | 3 (2) | – | 3 (2) |
| Liver disease | 3 (2) | 1 (3) | 2 (1) |
| Kidney disease | 2 (1) | – | 2 (1) |
| History of cancer | 11 (6) | – | 11 (7) |
| Immune disease | 2 (1) | – | 2 (1) |
| History of smoking | 7 (4) | – | 7 (5) |
| Parkinson's disease | 5 (3) | – | 5 (3) |
| Heart disease | 12 (7) | 1 (3) | 11 (7) |
| Other | 32 (18) | 4 (13) | 28 (19) |
| Treatment | |||
| Current GD Treatment, no. (%) | 127 (70) | 10 (32) | 117 (78) |
|
86 (48) | 9 (29) | 77 (51) |
|
41 (23) | 1 (3) | 40 (27) |
| Total Years of Tx, mean (sd), y | 16.5 (9.3) | 5.5 (3.3) | 17.3 (9.1) |
AJ indicates Ashkenazi Jewish; BMI, body mass index; and Tx, treatment.
a
ERT included imiglucerase, velaglucerase alfa, taliglucerase alfa.
b
SRT included eliglustat.